Literature DB >> 32680921

FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.

Li Xiao1, Xiaodi Li1, Zekun Mu1, Jianwen Zhou2, Peng Zhou3, Chen Xie1, Songshan Jiang4.   

Abstract

Malignant glioma constitutes one of the fatal primary brain tumors in adults. Such poor prognosis calls for a better understanding of cancer-related signaling pathways of this disease. Here we elucidate a MYC-miRNA-MXI1 feedback loop that regulates proliferation and tumorigenesis in glioma. MYC suppressed MXI1 expression via microRNA-155 (miR-155) and the microRNA-23a∼27a∼24-2 cluster (miR-23a cluster), whereas MXI1, in turn, inhibited MYC expression by binding to its promoter. Overexpression of miR-155 and the miR-23a cluster promoted tumorigenesis in U87 glioma cells. Furthermore, fat mass and obesity-associated protein (FTO), an N6-methyladenosine (m6A) RNA demethylase, regulated the loop by targeting MYC. The ethyl ester form of meclofenamic acid (MA2) inhibited FTO and enhanced the effect of the chemotherapy drug temozolomide on suppressing proliferation of glioma cells and negatively regulated the loop. These data collectively highlight a key regulatory circuit in glioma and provide potential targets for clinical treatment. SIGNIFICANCE: These findings elucidate a novel feedback loop that regulates proliferation in glioma and can be targeted via inhibition of FTO to enhance the efficacy of temozolomide. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32680921     DOI: 10.1158/0008-5472.CAN-20-0132

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  N6-methyladenosine and Neurological Diseases.

Authors:  Nan Zhang; Chunhong Ding; Yuxin Zuo; Yu Peng; Lielian Zuo
Journal:  Mol Neurobiol       Date:  2022-01-15       Impact factor: 5.590

2.  FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner.

Authors:  Aoshuang Xu; Jiasi Zhang; Liping Zuo; Han Yan; Lei Chen; Fei Zhao; Fengjuan Fan; Jian Xu; Bo Zhang; Yuyang Zhang; Xuejiao Yin; Qianwen Cheng; Su Gao; Jun Deng; Heng Mei; Zhiping Huang; Chunyan Sun; Yu Hu
Journal:  Mol Ther       Date:  2021-12-13       Impact factor: 11.454

3.  An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16.

Authors:  Liya Ma; Gen Li; Tianquan Yang; Li Zhang; Xinxin Wang; Xiaowen Xu; Hong Ni
Journal:  Cancer Chemother Pharmacol       Date:  2022-10-12       Impact factor: 3.288

Review 4.  The Key Role of RNA Modification in Breast Cancer.

Authors:  Yang Liu; Tong Zhu; Yi Jiang; Jiawen Bu; Xudong Zhu; Xi Gu
Journal:  Front Cell Dev Biol       Date:  2022-06-01

Review 5.  Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.

Authors:  Fusheng Zhang; Haiyang Liu; Meiqi Duan; Guang Wang; Zhenghou Zhang; Yutian Wang; Yiping Qian; Zhi Yang; Xiaofeng Jiang
Journal:  J Hematol Oncol       Date:  2022-07-06       Impact factor: 23.168

6.  No Association Between FTO Gene Polymorphisms and Central Nervous System Tumor Susceptibility in Chinese Children.

Authors:  Yuxiang Liao; Li Yuan; Zhiping Zhang; Ao Lin; Jingying Zhou; Zhenjian Zhuo; Jie Zhao
Journal:  Pharmgenomics Pers Med       Date:  2021-01-19

7.  Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.

Authors:  Haoyu Li; Qing Liu; Zihua Chen; Ming Wu; Chao Zhang; Jun Su; Yue Li; Chi Zhang
Journal:  Cell Death Dis       Date:  2021-03-05       Impact factor: 8.469

Review 8.  Epigenetics: Roles and therapeutic implications of non-coding RNA modifications in human cancers.

Authors:  Dawei Rong; Guangshun Sun; Fan Wu; Ye Cheng; Guoqiang Sun; Wei Jiang; Xiao Li; Yi Zhong; Liangliang Wu; Chuanyong Zhang; Weiwei Tang; Xuehao Wang
Journal:  Mol Ther Nucleic Acids       Date:  2021-05-01       Impact factor: 8.886

Review 9.  Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug.

Authors:  Wen-Min Zhou; Bin Liu; Amin Shavandi; Lu Li; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

Review 10.  Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.

Authors:  Marcus Bauer; Christoforos Vaxevanis; Nadine Heimer; Haifa Kathrin Al-Ali; Nadja Jaekel; Michael Bachmann; Claudia Wickenhauser; Barbara Seliger
Journal:  Int J Mol Sci       Date:  2020-09-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.